Immunosuppression in a patient with ANCA Associated Vasculitis? How much is enough?

Key Points

• The aim is to determine the appropriate level of immunosuppression for treating ANCA-associated vasculitis.
• Design: Randomized trial
• Population: Patients with ANCA-associated vasculitis
• Analysis: Comparing various levels of immunosuppression
• Optimal immunosuppression levels identified based on patient outcomes.
• Reduction in disease activity with targeted immunosuppression levels reported.